user

The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Lee, Jay M.
Spicer, Jonathan
Nair, Santosh
Khattak, Adnan
Brown, Michelle
Meehan, Robert S.
Shariati, Nazly M.
Deng, Xuan
Samkari, Ayman
Chaft, Jamie E.
机构：
[1] Univ Calif Los Angeles, Div Thorac Surg, Los Angeles, CA USA
[2] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[3] Mid Florida Canc Centers, Orange City, FL USA
[4] One Clin Res, Perth, Australia
[5] Edith Cowan Univ, Perth, WA, Australia
[6] Moderna Inc, Cambridge, MA USA
[7] Merck & Co Inc, Rahway, NJ USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8116
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 3 study of epacadostat plus pembrolizumab with or without platinumbased chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715
    Garassino, M.
    Rubin, S.
    Zhao, Y.
    Luo, Y.
    Samkari, A.
    Hui, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S115 - S115
  • [22] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [23] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
    Schuler, Martin
    Ramalingam, Suresh S.
    Shi, Lei
    Neibauer, Melissa Whipple
    Frenkl, Tara
    Stojadinovic, Alexander
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
  • [24] Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
    Garassino, Marina Chiara
    Wakelee, Heather A.
    Spicer, Jonathan
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    Chen, Ke-Neng
    Dooms, Christophe Alfons
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston L.
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Yang, Jing
    Arunachalam, Ashwini
    Norquist, Josephine M.
    Keller, Steven M.
    Gao, Shugeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Niraparib (Nira) plus Pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
    Schuler, M.
    Ramalingam, S.
    Arora, S.
    Neibauer, Whipple M.
    Zho, J.
    Hazard, S.
    Frenkl, T.
    Stojadinovic, A.
    Peters, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 170 - 171
  • [26] KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non-Small-Cell Lung Cancer
    Jabbour, S. K.
    Cho, B. C.
    Bria, E.
    Kato, T.
    Bhosle, J.
    Gainor, J. F.
    Reguart, N.
    Wang, L.
    Morgensztern, D.
    Gurary, E. B.
    Ashraf, T. B.
    Lara-Guerra, H.
    Reck, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E440 - E441
  • [27] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] KEYNOTE-867: Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab in Patients with Unresected Stage I or II Non-Small-Cell Lung Cancer (NSCLC)
    Jabbour, S. K.
    Houghton, B.
    Robinson, A. G.
    Quantin, X.
    Wehler, T.
    Kowalski, D.
    Ahn, M. J.
    Erman, M.
    Giaccone, G.
    Borghaei, H.
    McLean, J.
    Xu, Y.
    Souza, F.
    Pall, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E376 - E377
  • [29] ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non-small cell lung cancer (mNSCLC) with high PD-L1 levels
    Awad, Mark M.
    Munteanu, Mihaela
    Zhao, Yufan
    Xu, Lu
    Samkari, Ayman
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
    O'Brien, Mary
    Paz-Ares, Luis
    Marreaud, Sandrine
    Dafni, Urania
    Oselin, Kersti
    Havel, Libor
    Esteban, Emilio
    Isla, Dolores
    Martinez-Marti, Alex
    Faehling, Martin
    Tsuboi, Masahiro
    Lee, Jong-Seok
    Nakagawa, Kazuhiko
    Yang, Jing
    Samkari, Ayman
    Keller, Steven M.
    Mauer, Murielle
    Jha, Nitish
    Stahel, Rolf
    Besse, Benjamin
    Peters, Solange
    LANCET ONCOLOGY, 2022, 23 (10): : 1274 - 1286
12345